author-photo

Benjamin L. Woolbright

University of Kansas

67

Papers

1667

Citations

Citation Trend

Filter By

Papers (46) Sort By

Journal Conference Others

PDK2: An Underappreciated Regulator of Liver Metabolism

2021
- Benjamin L. Woolbright
- Robert A. Harris
Show All
- Source
- Cite
- Save
Citations (0)
Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex.

2021 Cell Death and Disease
Show All
- Source
- Cite
- Save
Citations (1)
Prostaglandin E2 as a therapeutic target in bladder cancer: From basic science to clinical trials

2020 Prostaglandins & Other Lipid Mediators
Show All
- Source
- Cite
- Save
Citations (5)
Safety, dose tolerance, pharmacokinetics, and pharmacodynamics of fosciclopirox (CPX-POM) in patients with advanced solid tumors.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Window of opportunity trial to characterize the safety, pharmacokinetics, and pharmacodynamics of fosciclopirox (CPX-POM) in cisplatin-ineligible muscle invasive bladder cancer patients.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Inflammation: Cause or consequence of chronic cholestatic liver injury

2020 Food and Chemical Toxicology
- Benjamin L. Woolbright
Show All
- Source
- Cite
- Save
Citations (5)
Abstract 5150: MIF-2 in bladder cancer: potential therapeutic target

2020
Show All
- Source
- Cite
- Save
Citations (0)
Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer

2020
Show All
- Source
- Cite
- Save
Citations (1)
Late Protective Effect of Netrin-1 in the Murine Acetaminophen Hepatotoxicity Model.

2020 Toxicological Sciences
Show All
- Source
- Cite
- Save
Citations (8)
Abstract 6405: Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting Notch signaling

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)